Management of lercanidipine overdose with hyperinsulinaemic euglycaemia therapy: case report.
This case report describes the first reported overdose of the dihydropyridine calcium channel blocker (CCB) lercanidipine. A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of lercanidipine. In the department he had a witnessed seizure within 15 minutes of arrival attributed to the overdose. Following immediate recovery of consciousness after the seizure, he had refractory hypotension and bradycardia which failed to respond to fluid resuscitation, glucagon therapy, and intravenous calcium. He went on to require vasopressor support with noradrenaline and was treated with high dose insulin therapy which was successful in achieving cardiovascular stability. Vasopressor therapy was no longer required within one half life of lercanidipine, and the total stay on intensive care was one day before transfer to a ward.Calcium channel blocker overdose is an uncommon but life-threatening overdose. Treatment for severe toxicity is similar to b-blocker overdose. Hypotension is treated with intravenous fluid therapy, intravenous calcium and possibly glucagon with vasopressor or inotropic support as required. Atropine is used to attempt reversal of bradycardia. High doses of intravenous insulin with intravenous dextrose as required (hyperinsulinaemic euglycaemia or HIET), has also been successfully reported. Experimental animal data suggests that HIET is of benefit and potentially superior to fluid therapy, calcium, glucagon and potentially vasopressor therapy. HIET effectively and sustainably reverses hypotension, bradycardia and improves myocardial contractility and metabolism. Current advice in calcium channel blocker overdose is to begin therapy early in toxicity, starting with a 1.0 IU/kg insulin bolus followed by an infusion of 0.5 IU/kg/hr of insulin and dextrose as required titrated to clinical response.
John Radcliffe Hospital, Headley Way, Headington, Oxford, OX39DU, UK. georgehadjipavlou@gmail.com
George
G
Hadjipavlou
Aqib
A
Hafeez
Ben
B
Messer
Tom
T
Hughes
D000931:Antidotes / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000506:poisoning*; D004095:Dihydropyridines / Q000506:poisoning / Q000627:therapeutic use*; D062787:Drug Overdose; D005934:Glucagon / Q000627:therapeutic use*; D005947:Glucose / Q000627:therapeutic use*; D015309:Glucose Clamp Technique / Q000379:methods; D006801:Humans; D007022:Hypotension / Q000139:chemically induced / Q000188:drug therapy*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D000931:Antidotes; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D007328:Insulin; D005934:Glucagon; D005947:Glucose; C060343:lercanidipine
Drugs. 2003;63(22):2449-72
14609358
Am J Cardiol. 1997 Jun 1;79(11):1570-1
9185662
Fundam Clin Pharmacol. 1998;12(6):607-12
9818292
Ann Emerg Med. 1993 Jul;22(7):1229-33
8517580
Crit Care Med. 1995 Jul;23(7):1251-63
7600835
J Toxicol Clin Toxicol. 1999;37(4):463-74
10465243
Crit Care. 2006;10(3):212
16732893
Am J Med. 1993 Oct;95(4):431-8
8213877
J Pharmacol Exp Ther. 1993 Nov;267(2):744-50
8246150